| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
Treatment of REH, REH/Ara-C, and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines with NL-1 (10-100 μM; 72 hours) results in concentration-dependent reductions of these cell lines. SUPB15 and NALM6 are inhibited by NL-1, with IC50 values of 29.48 µM and 94.26 µM, respectively. The IC50 values for NL-1, TOM1, BV173, NALM1, and JM1 are comparable, hovering about 60 µM [1]. Autophagy can be mediated by NL-1 treatment (60 μM; 6 hours; REH, REH/Ara-C cell lines), and NL-1-induced tumor cell death can be somewhat mitigated by autophagy inhibition [1]. The chemotactic capacity of REH and REH/Ara-C cells to move toward different chemoattractants is inhibited by NL-1 pretreatment. Chemotaxis in both REH and REH/AraC cells decreased in a dose-dependent manner in cells treated with NL1 [1].
|
|---|---|
| ln Vivo |
NL-1 (10 mg/kg; i.p.; daily; for 5 days; female NSG mice) therapy revealed antileukemic action in an in vivo mouse ALL model [1].
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) Cell Line Tested Concentrations: 10 μM, 20 μM , 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM, 100 μM Incubation Duration: 72 hrs (hours) Experimental Results: diminished number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM) - 1. JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner. Autophagy assay[1] Cell Types: REH, REH/Ara-C Cell line Tested Concentrations: 60 μM Incubation Duration: 6 hrs (hours) Experimental Results: Induction of autophagy. |
| Animal Protocol |
Animal/Disease Models: 10 female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (6-8 months old) were injected with TOM-1 ALL cells [1]
Doses: 10 mg/kg Route of Administration: intraperitoneal (ip) injection; daily ; Lasts 5 days Experimental Results: Demonstrates anti-leukemic activity in an in vivo mouse ALL model. |
| References |
| Molecular Formula |
C₁₈H₂₅NO₃S
|
|---|---|
| Molecular Weight |
335.46
|
| Exact Mass |
335.156
|
| CAS # |
188532-26-5
|
| PubChem CID |
9819104
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.21
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
23
|
| Complexity |
454
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
QDYYSPGKYXWGSL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H25NO3S/c1-17(2,3)11-7-10(8-12(14(11)20)18(4,5)6)9-13-15(21)19-16(22)23-13/h7-8,13,20H,9H2,1-6H3,(H,19,21,22)
|
| Chemical Name |
5-[(3,5-ditert-butyl-4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione
|
| Synonyms |
NL1; NL 1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~745.25 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.20 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.20 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.20 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9810 mL | 14.9049 mL | 29.8098 mL | |
| 5 mM | 0.5962 mL | 2.9810 mL | 5.9620 mL | |
| 10 mM | 0.2981 mL | 1.4905 mL | 2.9810 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
